Abstract

The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.

Introduction

Non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancers, is one of the most frequent cancers to metastasize to brain [1–3]. It is estimated that about 30% to 50% of patients with metastatic NSCLC will develop brain metastasis [4,5]. Clinical studies have demonstrated that survival time is significantly reduced after the occurrence of brain metastases in NSCLC patients [6]. The current treatment options for NSCLC with brain metastases include surgery, radiotherapy and chemotherapy. The efficacy of conventional systemic chemotherapy of brain metastases of NSCLC patients is limited due in large part to the blood–brain barrier (BBB) [2,7,8]. Higher incidences of brain metastases for patients with epidermal growth factor receptor (EGFR)-mutant metastatic NSCLC were found compared to EGFR wild type [9,10]. Several generations of EGFR tyrosine kinase inhibitors (TKIs) have been found to be highly effective compared to chemotherapy for NSCLC patients with brain metastases [11–14]. Recent pre-clinical and clinical studies suggest that some third-generation inhibitors can cross the BBB and show anti-tumor activity [15–18].

Osimertinib (AZD9291), a third-generation inhibitor of mutant EGFR, has been approved by the United States Food and Drug Administration (FDA) for EGFR T790 M–positive NSCLC [19,20]. Osimertinib was highly active in patients with lung cancer with the EGFR T790 M mutation [21–25], and is more efficacious compared to standard first line therapies [21,26–28]. Osimertinib showed higher concentrations in mouse brain tissue compared to plasma [29]. Osimertinib has improved BBB penetration ability and has potential for NSCLC patients with brain metastasis [1,30,31]. Koba et al. [32] reported that NSCLC patients containing an EGFR T790 M mutation with multiple brain metastases showed a strong response to
osimertinib within 2 weeks without radiation therapy. Further, Xie et al. [33], in a retrospective study, showed that osimertinib is effective for patients with progressing brain metastases and that radiation therapy is not needed before osimertinib treatment. Osimertinib showed high efficacy in a leptomeningeal carcinomatosis (LMC) model with EGFR-mutant lung cancer [34], against lung cancer with multiple HER2 aberrations [35], induced apoptosis in oral epidermoid and colorectal cancer cells [36,37], and showed good efficacy against breast cancer with L755P and L755S mutations [38].

In the present study, we established an imageable orthotopic xenograft mouse model of PC-9 expressing green fluorescence protein (PC-9-GFP) growing in the brain and determined the efficacy of osimertinib compared with conventional chemotherapy.

**Materials and Methods**

**Cell lines and Cell Culture**

The PC-9-GFP human EGFR-mutant NSCLC cell line with stable high-expression of GFP (AntiCancer, Inc., San Diego, CA) was maintained in RPMI-1640 (Mediatech, Inc. Manassas, VA) with 10% fetal bovine serum. All media were supplemented with penicillin and streptomycin. Cells were cultured at 37 °C with 95% air and 5% CO2.

**Mice**

Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 6–7 weeks old, were used in this study. The animals were fed an autoclaved laboratory rodent diet. All animal studies were conducted...
in accordance with the principles and procedures outlined in the National Institute of Health Guide for the Care and Use of Animals under Assurance Number A3873–1. Animals were anesthetized by subcutaneous injection of a ketamine mixture (0.02 ml solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine maleate). The animals were observed on a daily basis and humanely sacrificed by CO₂ inhalation if they met the following humane endpoint criteria: severe tumor burden (more than 20 mm in diameter), prostration, significant body weight loss, difficulty breathing, rotational motion and body temperature drop.

**Subcutaneous Tumor Growth**

PC-9-GFP cells growing in culture were harvested by trypsinization and washed two times with phosphate-buffered saline (PBS, Mediatech, Inc. Manassas, VA). Cells (2 × 10⁶) were injected subcutaneously into the right flank of mice in a total volume of 100 μl PBS. The subcutaneous tumors were used as the source of tissue for orthotopic implantation into the brain.

**Surgical Orthotropic Implantation (SOI) for Establishment of Brain Implantation Model**

Tumor pieces (1 mm³) derived from PC-9-GFP subcutaneous tumors growing in the nude mouse were implanted by surgical orthotopic implantation (SOI) onto the left intracranial space of mice. Briefly, a small incision (0.4–0.5 cm) on the top of the head was made and osteotomy was performed with a sharp pointed scalpel to make a flap. A single tumor fragment (1 mm³) was inserted to the subcranial space from the flap to establish the brain tumor model. The wound was closed with 6–0 nylon suture (Ethilon, Ethicon, Inc., Bridgewater, NJ, USA). All procedures of the operation described above were performed with a 7× microscope.

**Treatment Study Design**

The mouse models were randomized into 3 groups of 8 mice each (Figure 1A): G1, untreated control; G2, cisplatinum (CDDP, 6 mg/kg, intraperitoneal injection [i.p.], once a week for 2 weeks) + pemetrexed (PEM, 100 mg/kg, i.p., once a week for 2 weeks); G3, AZD 9291 (25 mg/kg/day, oral gavage, 14 consecutive days). Treatment started when all tumors reached 10–20 mm³. Tumor length, width and mouse body weight were measured twice in a week using fluorescence imaging. Tumor volume was calculated with the following formula: Tumor volume (mm³) = length (mm) × width (mm) × width (mm) × 1/2. Data are presented as mean ± standard error of the mean (SEM).

**Histological Analysis**

Fresh tumor samples were fixed in 10% formalin and embedded in paraffin before sectioning and staining. Tissue sections were deparaffinized in xylene and rehydrated in an ethanol series. Hematoxylin and eosin (HE) staining was performed according to standard protocol. Ki-67 immunofluorescence staining with anti-Ki-67 antibody (Abcam Ltd., Cambridge, MA), in combination with diaminobenzidine (DAB, Dako Japan Inc., Kyoto, Japan) staining, and hematoxylin counterstaining was performed according to manufacturer’s protocols.

**Statistical Analysis**

All statistical analyses were performed by statistical software EZR (Saitama Medical Center, Jichi Medical University), which is a graphical-user interface for R (The R Foundation for Statistical Computing, version 3.4.1). It is a modified version of R commander (version 2. 4–0) including statistical functions for biostatistics. A normal distribution was assessed with the Shapiro–Wilk test. The Bartlett’s test was used to verify the homogeneity of variances across groups. One-way ANOVA with Tukey HSD for post hoc analysis was used for the parametric test for inter-group comparison. Kruskal-Wallis with Steel-Dwass for post hoc analysis was used as the non-parametric test for inter-group comparison. All P-values were two-sided and P-values of 0.05 or less were considered statistically significant.

**Figure 3.** Tumor histology. (A) Untreated control. Low-power field (LPF). (B) Untreated control. High-power field (HPF). (C) CDDP + PEM treated. (LPF). (D) CDDP + PEM treated. (HPF). (E) AZD 9291 treated. (LPF). (F) AZD 9291 treated. (HPF). Scale bars: 100 μm.
Results

Efficacy of AZD9291 and CDDP + PEM on PC-9 Growing in the Brain

AZD9291 significantly regressed the NSCLC brain metastasis tumors compared to the untreated control and CDDP + PEM groups (AZD9291 vs. untreated control: \( P = .006 \), AZD9291 vs. CDDP + PEM: \( P = .004 \), Steel-Dwass test, Figure 1) on day 14 after initiation of treatment. The tumor had totally regressed at day 11 in one mouse of the AZD9291 group. CDDP + PEM slightly inhibited tumor growth, although there was no significant difference between the CDDP + PEM and the untreated control groups (\( P = .98 \), Figure 1B). Mean tumor volumes at day 14 were as follows: control: 125.3 ± 38.1; CDDP + PEM: 80.1 ± 7.13; and AZD9291: 7.1 ± 2.4 (Figure 2, A and B). The effect of treatment on relative tumor volume is presented in Figure 2B.

Histology of the Treated and Untreated Tumors in the Brain

Figure 3 shows the tumor histology of each group. The tumor tissue of the control group mainly comprised viable highly-dense cancer cells with nuclear atypia and atypical mitosis which could be detected in high-power fields (HPF). Spreading cancer cells in the tumor section could be observed in low-power fields (LPF). Tumors treated with CDDP+PEM also comprised highly-dense cancer cells which could be detected by both HPF and LPF, although the cancer-cell density was lower than the control. Only a small area of cancer cells was detected from the LPF of AZD9291-treated tumors with cancer-cell density lower than the control and CDDP+PEM groups. In addition, more scar tissue and hemosiderin deposition in the stroma were detected in the tumors treated by AZD9291.

Ki-67 Immunofluorescence Staining

In order to evaluate the proliferative capacity of cancer cells after treatment, immunofluorescence staining with the Ki-67 proliferation marker, which is present during all active phases of the cell cycle (G1, S, G2 and mitosis) and is absent in resting cells (G0), was performed on the tumor sections (Figure 4, A–C). Semi-quantitative Ki-67 positivity was evaluated as either (+++, moderate, 30–50% Ki-67-positive cells) in the tumor sections of control and CDDP+PEM treated groups and (−, none, 0%) in the AZD9291-treated group, suggesting of AZD9291 inhibited cancer-cell proliferation (Figure 4, A–D).

![Figure 4](image-url) Ki-67 immunohistochemistry. (A) Untreated control. Semi-quantitative Ki-67 positive frequency is evaluated as (+++). (B) CDDP+PEM treated. (+++). (C) AZD9291 treated. (−−−+). (D) % of Ki-67 positive cells in each group. Scale bars: 100 μm. Error bars ± SEM.
**Effect of Treatment on Body Weight**

Mouse body weight was measured pre-treatment and post-treatment, and body weight relative to the initial tumor volume was calculated. There was no significant difference in body weight between pre- and post-treatment in any group (Figure 5). There were no other observed side effects.

**Discussion**

Several first-line treatment options have been developed for patients with NSCLC containing an EGFR-TKI–sensitizing mutation [1,39]. However, approximately one-third of patients with NSCLC undergo disease progression during treatment with these first-line therapies due to brain metastases [40,41]. In the present study, evaluation of first-line treatment CDDP+PEM and a new targeted drug, osimertinib, for NSCLC brain metastasis were compared in a model of a GFP-labeled EGFR-mutant NSCLC growing in the brain of nude mice.

A combination of CDDP with PEM (PP) has been a standard treatment for patients with nonsquamous metastatic NSCLC [42–46]. However, PP therapy has limited efficacy if the disease metastasizes to the brain. Median progression-free survival and overall survival in the nonsquamous NSCLC patients with brain metastasis receiving PP therapy were reported to be 5 months and 11 months, respectively [45]. Chemotherapeutic agents for the treatment of lung-cancer brain metastasis have poor efficacy, which may be due to the BBB [2]. Both CDDP and PEM can cross the BBB to a limited extent. Cerebrospinal fluid penetration of CDDP and PEM are very low, reported to be 3.7% and 1.6%, respectively [47,48]. In the present study, the efficacy of the CDDP and PEM treatment on the NSCLC brain tumor models was limited and it could not significantly inhibit tumor growth.

Osimertinib is a third-generation of EGFR-tyrosine kinase inhibitors for the treatment of advanced EGFR-mutant NSCLC with improved BBB permeability [1,49]. A recent study suggests that osimertinib has CNS efficacy in patients with untreated EGFR-mutant NSCLC [50]. Rho et al. [51] showed the efficacy of two small-molecule EGFR-kinase inhibitors that are selective for T790 M-mutant isoforms of EGFR, in a preclinical model of lung cancer and found that both drugs were effective against intracranial metastasis of EGFR-mutant lung adenocarcinoma. Goss et al. [52] reported that osimertinib showed clinically-meaningful efficacy against patients with T790 M-positive advanced NSCLC and CNS metastases. Nishii et al. [53] demonstrated safety and efficacy of osimertinib for NSCLC patients with CNS lesions and poor performance status.

In the present study, we implanted GFP-labeled EGFR-mutant NSCLC tumors orthotopically to the mouse brain to track the intracranial tumors in real time without craniotomy and evaluate the drug’s efficacy. The tumor regression caused by osimertinib suggests this drug has potential to achieve efficacy against NSCLC brain metastasis in the clinic.

**Conflicts of Interest**

The authors declare that they have no competing interests.

**References**

[1] Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, and Grist M, et al (2016). Preclinical comparison of osimertinib with Other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22(20), 5130–5140.

[2] Lee SH (2012). Role of chemotherapy on brain metastasis. Prog Neurosurg 25, 110–114.

[3] Shin DY, Na II, Kim CH, Park S, Back H, and Yang SH (2014). EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol 9 (2), 195–199.

[4] Arrieta O, Villarreal-Garza C, Zamora J, Blake-Cerde M, de la Mata MD, Zavala DG, Muñiz-Hernández S, and de la Garza J (2011). Long-term survival in patients with non-small cell lung cancer and synchronous brain metastases treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol 6, 166.

[5] Jang T, Su C, Li X, Zhao C, Zhou F, Ren S, Zhou C, and Zhang J (2016). EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol 11(10), 1718–1728.

[6] Noronha V, Joshi A, Gokarn A, Sharma V, Patil V, Janu A, Purandare N, Chougule A, Jambhekar N, and Prabhash K (2014). the importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract 2014856156.

[7] Edelman MJ, Belani CP, Scinski MA, Ansari RH, Ohsaki K, Chen R, Monberg MJ, and Treat J, Alpha Oncology Research Network (2010). Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paxitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 5, 110–116.

[8] Balzé F, Gervais R, Lema H, Hueuxes B, Berard P, Paulinot D, Bota S, Monnet I, Chajara A, and Robinet G, et al (2011). Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFP 07-01). Ann Oncol 22, 2466–2470.

[9] Hu, F, De Caluwé A, Anderson D, Nicolò A, Toriiami T, and Ho C (2016). Osimertinib mutant status on brain metastases from non-small cell lung cancer. Lung Cancer 96, 101–107.

[10] Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, Lin W, Zheng W, and Xie X (2017). Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 9(8), 2510–2520.

[11] Rosell R, Carcereny E, Gervais R, Vornagenero A, Massuti B, Felpu P, Palmero R, García-Gomez R, Pallares C, and Sanchez JM, et al (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239–246.

[12] Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, and Mishima M (2012). Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70, 399–405.

[13] Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlow S, Tsai CM, and Boyer M, et al (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31, 3327–3334.

[14] Baik CS, Chamberlain MC, and Chow LQ (2015). Targeted therapy for brain metastases in EGFR-mutated and ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 10, 1268–1278.

[15] Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, and Lee JS (2012). Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77(3), 556–560.

[16] Porta R, Sánchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, and Salinas P, et al (2011). Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 37(3), 624–631.

[17] Hoffknochel P, Tufman A, Wehler T, Pelzer T, Wiedrowd R, Schütz M, Serke M, Stöhlmacher-Williams J, Märent A, and Maria Huber R, et al (2015). Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 10, 156–163.

[18] Schuler M, Wu YL, Hirsh V, O’Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zarulina V, and Yang JC (2016). First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 11, 380–390.
